Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: J Autoimmun. 2014 Jan 2;52:64–73. doi: 10.1016/j.jaut.2013.12.014

Figure 1. Recombinant IgG2a Fc multimers (M045) improve disease severity in EAMG.

Figure 1

Clinical score was evaluated in M045, IVIG and PBS treated mice as described in materials and methods. (a) The average clinical scores during the 45 day observation period are shown for the four groups. (b) Disease severity was significantly lower in M045 and IVIG-treated mice compared with the PBS treated tAChR-immunized controls. (c) M045 and IVIG treatment significantly suppresses the disease severity in mice with established EAMG. The values in the bar diagram represent the mean ± SEM of three separate experiments. Significance at p<0.05. *, compared to PBS.